SBIR FAST-TRACK AWARD (PHASE I STUDY BASE REQUIREMENT WITH OPTION FOR PHASE II STUDY) CONTINUOUS MONITORING OF ALCOHOL USE BY WEARABLE BIOSENSORS

目前可用于测量血液酒精浓度(BAC)和酒精在个体中的生物反应的方法大多限于繁琐的呼气测定仪或血液测试。NIAAA寻求一种可穿戴或以其他方式保密的设备，能够实时测量、记录和存储血液酒精水平。酒精生物传感器是谨慎的，并提供持续的酒精使用监测，将推动NIAAA在研究、治疗、康复和康复领域的使命。 根据这份合同进行的研究旨在开发下一代可穿戴式连续酒精监测(CAM)技术，旨在实时测量、记录和存储血液酒精浓度(BAC)。这份SBIR“快速通道”型合同包含SBIR第一阶段研究的基本合同要求和SBIR第二阶段研究的合同选项。 SBIR第一阶段研究(基本合同要求)将进行分析，以验证一种新的、谨慎的、可穿戴的、稳定的、选择性的和高灵敏度的酶生物传感器和算法，该传感器和算法可以实时和直接从间质液体中检测酒精，并评估其在类似人血清的混合物中的浓度。 SBIR第二阶段研究(合同选项)将进一步改进和优化传感器探头的性能，并将其集成到紧凑、轻便的原型设备中，准备用于研究研究，从而有效地向私人投资者展示其支持商业化的潜力。

Current methods available to measure Blood Alcohol Concentration (BAC) and the biological response of alcohol in individuals are mostly limited to cumbersome breathalyzer or blood tests. The NIAAA seeks a wearable or otherwise discreet device capable of measuring, recording, and storing blood alcohol levels in real time. Alcohol biosensors that are discreet and provide continuous alcohol use monitoring will advance the mission of the NIAAA in the arenas of research, treatment, rehabilitation, and recovery. The research under this contract is toward the development of next-generation, wearable continuous alcohol monitoring (CAM) technology designed to measure, record, and store Blood Alcohol Concentration (BAC) in real time. This SBIR “Fast-Track”-type contract contains a base contract requirement for an SBIR Phase I Study and a contract option for an SBIR Phase II Study. The SBIR Phase I Study (base contract requirement) will perform analysis toward validating the technology of a new, discreet, wearable, stable, selective and highly sensitive enzymatic biosensor and algorithms that can detect alcohol in real-time and directly from interstitial fluid and evaluate its concentration in a mixture similar to human serum. The SBIR Phase II Study (contract option) will further refine and optimize the performance of the sensor probe and integrate it into a compact, lightweight prototype device ready to use in research studies that will effectively demonstrate its potential to private investors to support commercialization.